# US 2026/0085347 A1 · Detecting mutations and ploidy in chromosomal segments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085347 A1
- Document ID: US20260085347A1
- Status: Published application
- Kind: A1
- Application number: 19/410,320
- Filed: 2025-12-05
- Published: 2026-03-26
- Earliest claimed: 2014-04-21
- Assignees: Natera, Inc.
- Applicants: Natera, Inc.
- Inventors: Joshua BABIARZ; Tudor Pompiliu CONSTANTIN; Lane A. EUBANK; George GEMELOS; Matthew Micah HILL; Huseyin Eser KIRKIZLAR; Matthew RABINOWITZ; Onur SAKARYA; Stymir SIGURJONSSON; Bernhard ZIMMERMANN
- Web page: https://patentgrep.com/patent/US20260085347A1

## CPC

- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/68: involving nucleic acids
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6811: Selection methods for production or design of target specific oligonucleotides or binding molecules
- C12Q 1/6848: characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention provides methods, systems, and computer readable medium for detecting ploidy of chromosome segments or entire chromosomes, for detecting single nucleotide variants and for detecting both ploidy of chromosome segments and single nucleotide variants. In some aspects, the invention provides methods, systems, and computer readable medium for detecting cancer or a chromosomal abnormality in a gestating fetus.

## Claims

### Claim 1

A method for identifying one or more tumor-specific variants in a biological sample of a subject having cancer or suspected of having cancer, the method comprising:
(a) performing whole genome sequencing or whole exome sequencing on nucleic acids derived from a tumor biopsy sample of the subject and identifying 100 to 20,000 tumor-specific variants;
(b) selectively enriching 100 to 20,000 target loci from a first cell-free DNA sample derived from the biological sample of the subject to obtain a first set of selectively enriched DNA molecules, wherein the 100 to 20,000 target loci each includes at least one of the 100 to 20,000 tumor-specific variants identified in the tumor biopsy sample of the subject, wherein the selective enrichment of the target loci is performed using 100 to 20,000 target-specific primers or probes in one reaction volume; and
(c) obtaining sequence reads of a portion of the first set of selectively enriched DNA molecules, and
(d) identifying one or more of the tumor-specific variants present in the first cell-free DNA sample from the sequence reads,
wherein a first target locus and a second target locus are within 0.1 kb of each other, wherein a first variant at the first target locus and a second variant at the second target locus are phased alleles.

### Claim 2 (depends on 1)

The method of claim 1, wherein the presence of the first variant in the sequence reads increases the probability of the presence of the second variant.

### Claim 3 (depends on 1)

The method of claim 1, wherein the absence of the first variant in the sequence reads decreases the probability of the presence of the second variant.

### Claim 4 (depends on 1)

The method of claim 1, wherein the first target locus and the second target locus are within 0.01 kb of each other.

### Claim 5 (depends on 1)

The method of claim 1, wherein at least one of the first set of selectively enriched DNA molecules comprises the first target locus and the second target locus, wherein the first target locus and the second target locus are single nucleotide polymorphism or variant loci.

### Claim 6 (depends on 1)

The method of claim 1, wherein the tumor biopsy sample of the subject includes a tumor tissue from a solid tumor.

### Claim 7 (depends on 1)

The method of claim 1, wherein the biological sample comprises a blood, plasma, serum, or urine sample.

### Claim 8 (depends on 1)

The method of claim 1, wherein the first cell-free DNA sample comprises circulating tumor DNA.

### Claim 9 (depends on 1)

The method of claim 1, wherein step (b) comprises selectively enriching 100 to 1,000 target loci, wherein the selective enrichment of the target loci is performed using 100 to 1,000 target locus-specific primers or probes in one reaction volume.

### Claim 10 (depends on 9)

The method of claim 9, wherein the first set of selectively enriched DNA molecules are tagged with a plurality of different molecular barcodes.

### Claim 11 (depends on 1)

The method of claim 1, wherein step (a) comprises selectively enriching 1,000 to 10,000 target loci, wherein the selective enrichment of the target loci is performed using 1,000 to 10,000 target locus-specific primers or probes in one reaction volume.

### Claim 12 (depends on 11)

The method of claim 11, wherein the first set of selectively enriched DNA molecules are tagged with a plurality of different molecular barcodes.

### Claim 13 (depends on 1)

The method of claim 1, wherein step (c) comprises obtaining sequence reads with a depth of read of at least 3,000 per target locus.

### Claim 14 (depends on 1)

The method of claim 1, wherein step (c) comprises obtaining sequence reads with a depth of read of 10,000 to 250,000 per target locus.

### Claim 15 (depends on 1)

The method of claim 1, wherein the subject is a human subject.

### Claim 16 (depends on 1)

The method of claim 1, wherein the cancer is colorectal cancer, lung cancer, bladder cancer, or breast cancer.

### Claim 17 (depends on 1)

The method of claim 1, wherein the method further comprises the steps of:
selectively enriching 100 to 20,000 target loci from a second cell-free DNA sample obtained from a second biological sample of the subject to obtain a second set of selectively enriched DNA molecules, wherein the 100 to 20,000 target loci each includes at least one of the 100 to 20,000 tumor-specific variants identified in the tumor biopsy sample of the subject, and wherein the selective enrichment of the target loci is performed using 100 to 20,000 target-specific primers or probes in one reaction volume; and
obtaining sequence reads of a portion of the second set of selectively enriched DNA molecules, and
identifying one or more tumor-specific variants present in the second cell-free DNA sample from the sequence reads.

### Claim 18 (depends on 17)

The method of claim 17, wherein the first biological sample and the second biological sample are taken from the same subject at different points in time.

### Claim 19 (depends on 17)

The method of claim 17, wherein the first biological sample and the second biological sample are taken from different bodily tissues or fluids.

### Claim 20 (depends on 17)

The method of claim 17, wherein the method further comprises detecting recurrence and/or metastases of the cancer from the tumor-specific variants detected in the first cell-free DNA sample or the second cell-free DNA sample.

### Claim 21 (depends on 17)

The method of claim 17, wherein the method identifies a tumor-specific variant present in the first cell-free DNA sample or the second cell-free DNA sample at a limit of detection of less than or equal to 0.015%.

### Claim 22 (depends on 21)

The method of claim 21, wherein the limit of detection is calculated by LOD-mr5, LOD-zs5.0, or LOD-zs5.0-mr5.
